Bortezomib CAS 179324-69-7 Munditia ≥99.0% (HPLC) API Factory Puritas
Copia Bortezomib intermedia cum High puritate
(1S,2S,3R,5S)-(+)-2,3-Pinanediol CAS 18680-27-8.
(1R,2R,3S,5R)-(-)-2,3-Pinanediol CAS 22422-34-0
Bortezomib CAS 179324-69-7
| Nomen chemicum | Bortezomib |
| Synonyma | Velcade, MG-341, PS-341 . |
| CAS Number | 179324-69-7 |
| CATTUS Number | RF-API65 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C19H25BN4O4 |
| M. Pondus | 384.24 |
| Liquescens punctum | 122.0~ 124.0℃ |
| Density | 1.214 |
| Index refractivus | 1.564 |
| Solubilitas | Solutum in Chloroforme, DMSO, Ethanol et Methanol |
| Stabilitas | Hygroscopic et umor sensitivus |
| Shipping Condition | Uit sub Ambient Temperature |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba vel Off-White pulveris |
| Puritas / Analysis Methodus | ≥99.0% (HPLC) |
| Damnum in Siccatio | ≤0.50% |
| Residere in Ignition | ≤0.20% |
| Optical gyrationis | -41.0° ~ -46.0° |
| Grave metallum | ≤20ppm |
| Acorem | 4.0~7.0 |
| Isomer | ≤0.50% |
| una immunditia | ≤0.50% |
| Totalis immunditias | ≤1.0% |
| RELICTUM Solvents | |
| Methanol | ≤0.30% |
| Dichloromethane | ≤0.05% |
| Hexane | ≤0.04% |
| Ethyl Acetate | ≤0.50% |
| Test Standard | Enterprise Standard |
| Consuetudinem | API |
sarcina: Utrem, aluminium foil, pera, cardboard Drum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica et supplementum Bortezomib (CAS: 179324-69-7) cum qualitate alta, API.
Bortezomib, sub Velcade nomine notam apud alios venditum, est anti-cancer medicinalis usus multiplicem myeloma et mantellum cellae lymphoma tractare.Bortezomib in Civitatibus Foederatis Americae ad usum medicinae anno 2003 et in Unione Europaea anno 2004 probatus est. In indice Medicamentorum Essentialium Mundi Salus Organizatio est.Bortezomib est primus inhibitor proteasome approbandus b US FDA pro myeloma multiplex, cancer sanguinis.Inhibitor convertitur 26S proteasome-dolium multiprotein-formatum particulae in nucleo et cytosol omnium cellularum eukaryoticorum inventarum.Bortezomib est inhibitor selectivus et robustus 26S proteasome, id est acidi boronici dipeptidi derivativi.Studia humana cancer cellae pancreaticae demonstrant Bortezomib ut reticulum endoplasmicum (ER) kinasum PKR inhibere et accentus augere ER, ad apoptosim ducere.
